The impact of mpMRI-targeted vs systematic biopsy on the risk of prostate cancer downgrading at final pathology.
Sorce G, Stabile A, Pellegrino F, Mazzone E, Mattei A, Afferi L, Serni S, Minervini A, Roumiguiè M, Malavaud B, Valerio M, Rakauskas A, Marra G, Gontero P, Porpiglia F, Guo H, Zhuang J, Gandaglia G, Montorsi F, Briganti A.
Sorce G, et al. Among authors: marra g.
World J Urol. 2024 Apr 22;42(1):248. doi: 10.1007/s00345-024-04963-w.
World J Urol. 2024.
PMID: 38647689